Fravel Michelle A, Ernst Michael E, Woods Robyn L, Orchard Suzanne G, Polkinghorne Kevan R, Wolfe Rory, Wetmore James B, Nelson Mark R, Bongetti Elisa, Murray Anne M, Zoungas Sophia, Zhou Zhen
Department of Pharmacy Practice and Science, College of Pharmacy, The University of Iowa, Iowa City, Iowa, USA.
Department of Family Medicine, Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA.
J Am Geriatr Soc. 2025 Apr;73(4):1082-1093. doi: 10.1111/jgs.19319. Epub 2024 Dec 18.
The effect of statin therapy on kidney function among older adults is unclear.
To examine the association between statin use and changes in estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR), positive or negative, in an older adult cohort with versus without chronic kidney disease (CKD) at baseline.
This analysis included 18,056 participants aged ≥65 years with versus without CKD at baseline in a randomized trial of low-dose aspirin, who had no prior cardiovascular events, major physical disability, or dementia initially. Outcome measures included eGFR and UACR. Linear mixed-effects models were used to estimate the associations of baseline statin use versus no use with eGFR and UACR changes over time. The inverse-probability of treatment-weighting technique was used for all analyses to address confounding by indication due to the lack of randomization in treatment assignment.
Statin use was not associated with change in eGFR, UACR, or incident CKD in participants with or without CKD at baseline (p > 0.05 for all associations). Subgroup analyses found no significant interactions between statin and age, sex, diabetes, country, and frailty status on any of the study outcomes.
Among adults ≥65 years of age, with and without CKD, statin therapy was not associated with improved or worsened kidney function. This data suggests that the decision to use versus not use statins in this population may be ideally guided by factors other than kidney health.
他汀类药物治疗对老年人肾功能的影响尚不清楚。
在一个基线时患有或未患有慢性肾脏病(CKD)的老年队列中,研究他汀类药物使用与估算肾小球滤过率(eGFR)和尿白蛋白与肌酐比值(UACR)的变化(无论正负)之间的关联。
这项分析纳入了18056名年龄≥65岁、基线时患有或未患有CKD的参与者,他们来自一项低剂量阿司匹林的随机试验,最初均无心血管事件、严重身体残疾或痴呆。结局指标包括eGFR和UACR。采用线性混合效应模型来估计基线时使用他汀类药物与未使用他汀类药物和eGFR及UACR随时间变化之间的关联。由于治疗分配缺乏随机化,所有分析均使用治疗权重的逆概率技术来处理因适应证导致的混杂因素。
在基线时患有或未患有CKD的参与者中,他汀类药物的使用与eGFR、UACR的变化或CKD的发生均无关联(所有关联的p>0.05)。亚组分析发现,在任何研究结局方面,他汀类药物与年龄、性别、糖尿病、国家和衰弱状态之间均无显著交互作用。
在65岁及以上患有或未患有CKD的成年人中,他汀类药物治疗与肾功能改善或恶化均无关联。该数据表明,在这一人群中决定是否使用他汀类药物,理想情况下可能由肾脏健康以外的因素指导。